•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Imexpharm marked a decade of EU-GMP implementation in 2026, reinforcing its position as Vietnam’s leading EU-GMP pharmaceutical manufacturer while accelerating market expansion through higher-value product portfolios and improved operational efficiency supported by strategic shareholders.
“The year 2026 marks the establishment and maintenance of Imexpharm's position as Vietnam's leading EU-GMP pharmaceutical manufacturer for a decade, built on a long-term strategic vision and consistent execution. The ‘Ten Years of EU-GMP’ also confirms the superior and hard-to-copy capabilities of Imexpharm's team in R&D, manufacturing, and quality management, ensuring that every medicine reaching patients provides absolute assurance of safety and treatment efficacy,” said Dr. Tran Thi Dao, a member of the Board of Directors and CEO, at the 2026 AGM held on April 22 in Ho Chi Minh City.
The company said the pharmaceutical sector is facing intensifying competition, rising standards, and narrowing margins, with growth increasingly shifting toward high-value products and high-tech medicines as basic generics become more saturated.
Imexpharm described the strategic shift required for the industry as moving from “growth by quantity” to “growth by value.” In this context, the EU-GMP platform built over the past decade is positioned as both a competitive advantage and a basis for entering higher value-added segments.
Globally, the company cited the patent cliff affecting many blockbuster drugs and M&A activity aimed at restructuring product portfolios for 2026–2030. It also noted that a more favorable regulatory environment for biosimilars in some large markets is shortening development timelines and costs, increasing competition and expanding treatment access.
At the 2026 AGM, Imexpharm said the global value share of biologics has exceeded 40% of total drug value and is projected to exceed 50% by 2030. It added that, according to Fortune Business Insights, Vietnam’s biologics share is similar, at around 40% of drug value, indicating significant potential for biologics and biosimilars in Vietnam and worldwide.
To respond to these shifts, the company said it aims to strengthen R&D capabilities, manage product lifecycles, and access new technologies. It also said it expects technology partnerships to become a strategic direction to boost research capabilities and long-term competitiveness, guided by risk governance combining EU-GMP manufacturing, R&D, and local market understanding.
Imexpharm said it has nearly 160 R&D projects that can be produced on its existing four-plant network. It also reported that it has begun studying and selecting a portfolio of nearly 150 products for the new Cat Khanh plant, with about half targeting chronic diseases.
Imexpharm outlined a 2026 growth plan amid geopolitical risks and volatile financial markets. The company targets revenue of VND 3,200 billion in 2026.
It also expects profitability indicators to maintain double-digit growth, including revenue up 9.8% year-on-year, pretax profit up 12.5% year-on-year, and EBITDA up 12.3% year-on-year.
“Ahead of 2026, Imexpharm continues to transform and rise to the times. Imexpharm stands before the opportunity to maximize its leading position in existing markets while accelerating into new growth lanes,” a member of the management team said.
The company said governance has been identified as a core foundation over nearly five decades, aligning with leading practices including the Vietnam Corporate Governance Code for Public Companies, the ASEAN Corporate Governance Scorecard, and international standards.
Imexpharm said it has implemented modern governance systems such as SAP S/4HANA Cloud Private Edition, IFRS, and enterprise risk management (ERM) to improve transparency, standardize operations, and boost performance.
Imexpharm reported that Q1 revenue reached VND 629 billion and pretax profit was VND 103 billion, up 8% year-on-year. The company said it continues to consolidate its domestic position, expand in the North, and increase international presence through EU-MAs and ASEAN licenses.
Beyond short-term results, Imexpharm said it is translating strategic directions into operational actions, including optimizing production costs as plants have depreciated over the past decade, focusing on high-technology products, diversifying its OTC portfolio through cooperation with modern pharmacy chains, and expanding reach in the northern region.
The company also stated that digital transformation and ESG integration are being implemented to improve efficiency and support sustainable development.
In the long term, Imexpharm said it aims to expand R&D and production of high-technology pharmaceuticals through investment in the Cat Khanh pharmaceutical technology park totaling nearly VND 1,500 billion.
Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…
